Next Generation Drug Conjugates (NDCs) Market Report 2026-2035, By Product, Type, and Geo

DESCRIPTION
TABLE OF CONTENTS
METHODOLOGY
DOWNLOAD PDF

Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035

USD 15.75B

MARKET SIZE, 2026

USD 42.55B

MARKET SIZE, 2035

11.7%

CAGR (2026-2035)

2026-2035

FORECAST PERIOD

NEXT GENERATION DRUG CONJUGATES MARKET SIZE, SHARE & GROWTH SNAPSHOT

next-generation-drug-conjugates-ndcs-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global next generation drug conjugates market is projected to grow from USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7% during the forecast period. The market was valued at USD 13.94 billion in 2025. Next generation drug conjugates are delivery systems that are biologically or chemically engineered targeting moieties (e.g., antibody, peptide, small molecules, oligonucleotides), a drug (e.g., cytotoxic, radionuclide, nucleic acid), a linker, and conjugation technologies that distinguish next generation conjugates from earlier generations.

KEY TAKEAWAYS

MARKET SNAPSHOT:
Base Year Market Size (2025): USD 13.94 Billion
Current Market Size (2026): USD 15.75 Billion
Forecast Market Size (2035): USD 42.55 Billion
CAGR (2026�2035): 11.7%
SEGMENT LEADERSHIP:
By Region: North America is projected to be the fastest-growing regional segment at a CAGR of 13.2% during the forecast period.
By Type: Peptide-radionuclide conjugate is projected to witness the highest CAGR of 14.6% between 2026 and 2035.
By Indication: Breast cancer is expected to dominate the global next generation drug conjugates market in 2025 with a share of 45.9%.
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
AstraZeneca, Daiichi Sankyo, and Novartis were identified as some of the star players in the global next generation drug conjugates market, given their strong market share and product footprint.
Avidity Biosciences and Bicycle Therapeutics have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The global next generation drug conjugates (NGDC) market is expanding rapidly, driven by the rising adoption of precision medicine frameworks and the increasing use of biomarker-guided diagnostics across oncology and other complex disease indications.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The next generation drug conjugates (NGDC) market is advancing rapidly, driven by innovations in targeting ligands, linker technologies, and payload engineering aligned with precision medicine and targeted biologic therapies. The rising global prevalence of cancer and complex chronic diseases is accelerating demand for highly selective, low-toxicity treatments. Expanding pipelines of antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and other ligand-based platforms are enabling precise delivery of potent therapeutics. Clinically validated, scalable technologies such as site-specific conjugation and advanced linkers are gaining traction, supporting improved outcomes, personalized treatment approaches, and alignment with evolving regulatory and payer expectations across major healthcare markets.

next-generation-drug-conjugates-ndcs-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers

Impact
Level

Increasing clinical success and regulatory approvals of antibody-drug conjugates
Technological advancements in linker chemistry and payload development

RESTRAINTS

Impact
Level

High development and manufacturing costs associated with complex biologics

OPPORTUNITIES

Impact
Level

Expansion of drug conjugates into non-oncology therapeutic areas
Increasing developments of novel conjugate platforms

CHALLENGES

Impact
Level

Complex clinical trial design and patient selection requirements

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing clinical success and regulatory approvals of antibody-drug conjugates

Increasing clinical success and regulatory approvals of antibody-drug conjugates are key drivers for the NGDC market, validating targeted delivery approaches, improving therapeutic outcomes, and encouraging investment in advanced conjugation technologies, thereby accelerating pipeline expansion and broader adoption across oncology and other disease indications.

Restraint: High development and manufacturing costs associated with complex biologics

High development and manufacturing costs associated with complex biologics act as a restraint, limiting accessibility and scalability, increasing pricing pressures, and posing challenges for smaller players in advancing and commercializing next generation conjugate therapies.

Opportunity: Expansion of drug conjugates into non-oncology therapeutic areas

Expansion of drug conjugates into non-oncology therapeutic areas presents a significant opportunity for the NGDC market, enabling broader clinical applications in cardiovascular, neurological, and autoimmune diseases, while driving innovation in targeted delivery platforms and diversifying revenue streams beyond oncology-focused treatments.

Challenge: Complex clinical trial design and patient selection requirements

Complex clinical trial design and stringent patient selection requirements pose a challenge, as biomarker-driven stratification, smaller target populations, and intricate protocols increase development timelines, operational costs, and regulatory complexity, potentially slowing overall product commercialization.

NEXT GENERATION DRUG CONJUGATES (NDCS) MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Utilizes its DXd (deruxtecan-based) payload platform in next generation ADCs such as HER2-targeting therapies for breast and gastric cancers	Provides enhanced potency and tumor penetration with improved response rates, addressing resistant and heterogeneous tumor profiles
	Develops pyrrolobenzodiazepine (PBD)-based ADCs targeting hematologic malignancies and expanding into solid tumor indications	Delivers ultra-potent payloads that enable effective treatment of aggressive and refractory cancers, improving patient outcomes in niche oncology segments

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The global next generation drug conjugates (NGDC) market is a highly interconnected ecosystem where biopharmaceutical companies, biotechnology firms and research institutions collaborate to develop targeted therapeutic solutions. Drug developers, along with specialized technology providers, enable advanced conjugation platforms integrating antibodies, peptides, and other targeting ligands with potent payloads. Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) support preclinical development, clinical trials, and commercialization of NGDCs. Regulatory bodies, healthcare systems, and reimbursement frameworks across regions such as North America and Europe facilitate the translation of clinical advancements into precision medicine, enabling broader adoption of targeted conjugate therapies.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Global Next Generation Drug Conjugates Market, by Product

In 2025, Enhertu dominated the next generation drug conjugates market due to its strong clinical efficacy, expanding global approvals, and rapid adoption across HER2-targeted cancers. Its widespread use in breast cancer and growing indications in lung and gastric cancers have significantly contributed to its leadership.

Global Next Generation Drug Conjugates Market, by Type

In 2025, antibody–small molecule drug conjugates accounted for the largest share of the market, driven by their ability to combine monoclonal antibody specificity with highly potent cytotoxic payloads. This structure enables precise tumor targeting while minimizing systemic toxicity, making them the most commercially successful and clinically advanced class within next generation drug conjugates.

Global Next Generation Drug Conjugates Market, by Target Ligand

In 2025, antibody-based targeting ligands held the dominant share in the next generation drug conjugates market due to their high specificity toward tumor-associated antigens such as HER2. Their ability to selectively bind cancer cells and deliver payloads efficiently has positioned antibodies as the preferred targeting mechanism in most approved and pipeline ADCs

Global Next Generation Drug Conjugates Market, by Payload Type

In 2025, small molecule payloads dominated the market, owing to their high cytotoxic potency and effectiveness in killing cancer cells upon internalization. Payloads such as topoisomerase inhibitors and microtubule inhibitors are widely used in ADCs, enabling strong anti-tumor activity even at low doses while maintaining controlled toxicity profiles

Global Next Generation Drug Conjugates Market, by Indication

In 2025, breast cancer accounted for the largest share of the next generation drug conjugates market, primarily due to the high prevalence of the disease and the strong clinical success of HER2-targeted ADCs such as Enhertu. Continuous advancements in targeted therapies and expanding treatment eligibility for HER2-low populations have further reinforced breast cancer as the leading indication segment.

REGION

North America to be fastest-growing region in market during forecast period

During the forecast period, North America is expected to emerge as a leading and fast-growing region in the global NGDC market, driven by its strong ecosystem of biopharmaceutical companies, advanced research institutions, and specialized oncology centers. A robust pipeline of antibody-drug conjugates and other targeted conjugates, coupled with significant investments in precision medicine, biomarker-driven trials, and regulatory support, continues to accelerate market growth across oncology and expanding therapeutic areas.

next-generation-drug-conjugates-ndcs-market Region

NEXT GENERATION DRUG CONJUGATES (NDCS) MARKET: COMPANY EVALUATION MATRIX

In the global next generation drug conjugates (NGDC) market, AstraZeneca is the star player, driven by its strong portfolio of approved antibody-drug conjugates and a robust pipeline leveraging advanced linker and payload technologies. The company continues to lead innovation in targeted oncology therapies through strategic collaborations and sustained R&D investments. AbbVie is an emerging leader, gaining momentum through its expanding conjugate-based pipeline and partnerships, particularly in oncology and immunology. Its focus on next generation conjugation platforms and targeted delivery systems positions it strongly to capture future growth opportunities in the evolving NGDC landscape.

next-generation-drug-conjugates-ndcs-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size, 2025 (Value)	USD 13.94 Billion
Market Forecast, 2035 (Value)	USD 42.55 Billion
Growth Rate	CAGR of 11.7 % from 2026–2035
Years Considered	2024–2035
Base Year	2025
Forecast Period	2026–2035
Units Considered	Value (USD Million/Billion)
Report Coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered	By Product: ENHERTU AMVUTTRA PLUVICTO TRODELVY Sacituzumab Tirumotecan (SAC-TMT) Zilebesiran 225Ac-PSMA-617 Other Commercialized Products Other Pipeline Products By Type: Antibody-Small Molecule Drug Conjugate Peptide-Radionuclide Conjugate Ligand-Oligonucleotide Conjugate Other Drug Conjugate Types By Target Ligand: Antibody Amino Sugar Peptide Other Targeting Ligands By Payload Type: Small Molecule Radionuclide Oligonucleotide Other Payload Types By Indication: Breast Cancer hATTR with Nolyneuropathy Prostate Cancer Primary Hyperlipidemia Other Indications
Regions Covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: NEXT GENERATION DRUG CONJUGATES (NDCS) MARKET REPORT CONTENT GUIDE

next-generation-drug-conjugates-ndcs-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Evaluating competitive positioning of NGDC pipelines	Analyzed pipelines of leading ADC and SMDC developers across clinical stages, target antigens, and payload innovations, benchmarking differentiation in efficacy, safety, and innovation focus	Support strategic decision-making by identifying whitespace opportunities, competitive gaps, and areas for pipeline expansion or licensing
Assessing high growth potential NGDC payloads	Supports strategic decision-making by identifying whitespace opportunities, competitive gaps, and areas for contract development and manufacturing service providers	Help evaluate key areas of entry in NGDC market for contract development and manufacturing service providers

RECENT DEVELOPMENTS

February 2025 : Alnylam collaborated with Regeneron to advance its RNAi therapeutic pipeline, including programs such as ALN-HTT02, targeting neurological and autoimmune diseases through RNA interference technologies.
June 2025 : Gilead announced the acquisition of Interius BioTherapeutics to advance in-vivo cell therapy technologies aimed at improving targeted cancer treatment approaches and expanding its oncology innovation platforms.

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE

PAGE NO

INTRODUCTION

EXECUTIVE SUMMARY

PREMIUM INSIGHTS

MARKET OVERVIEW

Explore booming antibody-drug conjugates market driven by technological advances and cross-sector opportunities.

4.1

INTRODUCTION

4.2

MARKET DYNAMICS

4.2.1

DRIVERS

4.2.1.1

INCREASING CLINICAL SUCCESS AND REGULATORY APPROVALS OF ANTIBODY-DRUG CONJUGATES

4.2.1.2

TECHNOLOGICAL ADVANCEMENTS IN LINKER CHEMISTRY AND PAYLOAD DEVELOPMENT

4.2.2

RESTRAINTS

4.2.2.1

HIGH DEVELOPMENT AND MANUFACTURING COSTS ASSOCIATED WITH COMPLEX BIOLOGICS

4.2.3

OPPORTUNITIES

4.2.3.1

EXPANSION OF DRUG CONJUGATES INTO NON-ONCOLOGY THERAPEUTIC AREAS

4.2.3.2

INCREASING DEVELOPMENTS OF NOVEL CONJUGATE PLATFORMS

4.2.4

CHALLENGES

4.2.4.1

CONCERNS RELATED TO BIOCOMPATIBILITY, SAFETY, AND ADVERSE IMMUNE RESPONSES

4.3

UNMET NEEDS AND WHITE SPACES

4.4

INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES

4.4.1

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE

4.4.2

PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE

4.4.3

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE

4.4.4

BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE

4.5

STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

INDUSTRY TRENDS

Navigate competitive pressures and pricing shifts in next-gen drug markets for strategic advantage.

5.1

PORTER’S FIVE FORCES ANALYSIS

5.1.1

THREAT OF NEW ENTRANTS

5.1.2

THREAT OF SUBSTITUTES

5.1.3

BARGAINING POWER OF BUYERS

5.1.4

BARGAINING POWER OF SUPPLIERS

5.1.5

INTENSITY OF COMPETITIVE RIVALRY

5.2

MACROECONOMIC OUTLOOK

5.2.1

INTRODUCTION

5.2.2

GDP TRENDS AND FORECAST

5.2.3

TRENDS IN GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET

5.3

VALUE CHAIN ANALYSIS

5.4

ECOSYSTEM ANALYSIS

5.5

PRICING ANALYSIS

5.5.1

INDICATIVE SELLING PRICE, BY KEY PLAYER, 2025 (USD)

5.5.2

AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)

5.5.3

AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)

5.6

KEY CONFERENCES & EVENTS

5.7

TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

5.8

INVESTMENT & FUNDING ACTIVITY

5.9

IMPACT OF US TARIFFS—NEXT-GENERATION DRUG CONJUGATES MARKET

5.9.1

INTRODUCTION

5.9.2

KEY TARIFF RATES

5.9.3

PRICE IMPACT ANALYSIS

5.9.4

IMPACT ON COUNTRIES/REGIONS

5.9.4.1

NORTH AMERICA

5.9.4.2

EUROPE

5.9.4.3

ASIA PACIFIC

5.9.5

IMPACT ON END-USE INDUSTRIES

5.9.5.1

HOSPITALS

5.9.5.2

SPECIALTY CLINICS AND CANCER CENTERS

5.9.5.3

OTHER SPECIALTY CARE SETTINGS

TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS

AI-driven innovations revolutionize next-gen drug conjugates, unlocking unprecedented market potential and client readiness.

6.1

TECHNOLOGY ANALYSIS

6.1.1

KEY TECHNOLOGIES

6.1.1.1

NEW-GENERATION PAYLOAD CHEMISTRIES

6.1.1.2

RADIOLIGAND/THERANOSTIC CONJUGATE ENGINEERING

6.1.2

ADJACENT TECHNOLOGIES

6.1.2.1

PROTEIN ENGINEERING/ANTIBODY ENGINEERING

6.1.3

COMPLEMENTARY TECHNOLOGIES

6.1.3.1

DIAGNOSTIC IMAGING/THERANOSTICS WORKFLOWS

6.2

TECHNOLOGY/PRODUCT ROADMAP

6.3

FUTURE APPLICATIONS

6.4

IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET

6.4.1

TOP USE CASES AND MARKET POTENTIAL

6.4.2

CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET

6.4.3

INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS

6.4.4

CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NEXT-GENERATION DRUG CONJUGATES MARKET

6.5

PIPELINE ANALYSIS

REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

Navigate complex global regulations and eco-standards to optimize compliance and sustainability strategies.

7.1

REGIONAL REGULATIONS AND COMPLIANCE

7.1.1

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

7.1.2

REGULATORY FRAMEWORK & REIMBURSEMENT

7.1.2.1

REIMBURSEMENT SCENARIO

7.1.3

INDUSTRY STANDARDS

7.1.4

CERTIFICATIONS, LABELING, AND ECO-STANDARDS

7.2

SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

CUSTOMER LANDSCAPE & BUYER BEHAVIOR

Unlock buyer dynamics by understanding stakeholder influence and unmet end-user needs.

8.1

DECISION-MAKING PROCESS

8.2

BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA

8.2.1

KEY STAKEHOLDERS IN BUYING PROCESS

8.2.2

KEY BUYING CRITERIA, BY END USER

8.3

ADOPTION BARRIERS & INTERNAL CHALLENGES

8.4

UNMET NEEDS FROM END USERS

8.5

MARKET PROFITABILITY

NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT

Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 55 Data Tables

9.1

INTRODUCTION

9.2

ENHERTU

9.2.1

BROAD CLINICAL ADOPTION AND REGULATORY EXPANSION OF TARGETED ADC THERAPIES DRIVE MARKET GROWTH

9.3

PLUVICTO

9.3.1

EXPANDING USE OF TARGETED RADIOLIGAND THERAPY IN PROSTATE CANCER TO DRIVE MARKET GROWTH

9.4

AMVUTTRA

9.4.1

ADVANCING RNAI THERAPEUTICS THROUGH DURABLE GENE SILENCING AND EXPANDED INDICATION REACH

9.5

TRODELVY

9.5.1

RISING GOVERNMENT APPROVALS FOR BREAST CANCER TREATMENTS TO DRIVE MARKET GROWTH

9.6

SACITUZUMAB TIRUMOTECAN

9.6.1

ADVANCING NEXT-GENERATION ADC PAYLOAD INNOVATION IN NDC MARKET

9.7

PATRITUMAB DERUXTECAN

9.7.1

ADVANCEMENTS IN HER3-DIRECTED ANTIBODY-DRUG CONJUGATES TO AID GROWTH

9.8

225AC-PSMA-617

9.8.1

POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO SUPPORT MARKET GROWTH

9.9

OTHER COMMERCIALIZED PRODUCTS

9.10

OTHER PIPELINE PRODUCTS

NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE

Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 25 Data Tables

119

10.1

INTRODUCTION

10.2

ANTIBODY–SMALL MOLECULE CONJUGATES

10.2.1

ENHANCED CLINICAL UTILITY AND TECHNOLOGICAL INNOVATION TO DRIVE MARKET

10.3

PEPTIDE–RADIONUCLIDE CONJUGATES

10.3.1

INNOVATIONS IN PRECISION ONCOLOGY APPLICATIONS AND TECHNOLOGICAL ADVANCEMENTS SUPPORT GROWTH

10.4

LIGAND–OLIGONUCLEOTIDE CONJUGATES

10.4.1

ENHANCED DELIVERY AND TISSUE TARGETING CAPABILITIES OF LIGAND–OLIGONUCLEOTIDE CONJUGATES DRIVE GROWTH

10.5

OTHER DRUG CONJUGATES

NEXT-GENERATION DRUG MARKET, BY TARGET LIGAND

Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 25 Data Tables

133

11.1

INTRODUCTION

11.2

ANTIBODIES

11.2.1

ADVANCEMENTS IN ANTIBODY ENGINEERING AND EXPANDING TARGET DIVERSITY DRIVE GROWTH

11.3

AMINO SUGARS

11.3.1

GROWING ADOPTION OF GALNAC-BASED LIVER-TARGETING PLATFORMS DRIVES EXPANSION

11.4

SMALL MOLECULES

11.4.1

EXPANDING USE OF SMALL-MOLECULE TARGETING LIGANDS IS BROADENING THE NEXT-GENERATION DRUG CONJUGATES MARKET

11.5

PEPTIDES

11.5.1

EXPANDING CLINICAL PIPELINES AND TUMOR-TARGETING INNOVATIONS PROPEL GROWTH

NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE

Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 19 Data Tables

147

12.1

INTRODUCTION

12.2

SMALL-MOLECULE PAYLOADS

12.2.1

RISING ADOPTION OF HIGHLY POTENT, NEXT-GENERATION PAYLOADS AND ADVANCED LINKER TECHNOLOGIES IS ACCELERATING GROWTH

12.3

OLIGONUCLEOTIDE PAYLOADS

12.3.1

RISING ADOPTION OF RNA-BASED GENE-SILENCING THERAPIES AND LONG-ACTING CONJUGATE PLATFORMS TO DRIVE MARKET

12.4

RADIONUCLIDE PAYLOADS

12.4.1

EXPANDING RADIOLIGAND THERAPY ADOPTION AND ADVANCEMENTS IN ISOTOPE TECHNOLOGIES SUPPORT MARKET GROWTH

NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION

Market Size & Growth Rate Forecast Analysis to 2035 in USD Million | 31 Data Tables

158

13.1

INTRODUCTION

13.2

BREAST CANCER

13.2.1

RISING INCIDENCE AND INCREASING ADOPTION OF TARGETED ADC THERAPIES TO DRIVE MARKET

13.3

HATTR WITH POLYNEUROPATHY

13.3.1

ADVANCEMENTS IN RNA-BASED GENE-SILENCING THERAPIES AND INCREASING DIAGNOSIS RATES ARE DRIVING GROWTH

13.4

PROSTATE CANCER

13.4.1

EXPANDING ADOPTION OF PSMA-TARGETED RADIOLIGAND THERAPIES IS DRIVING GROWTH

13.5

PRIMARY HYPERLIPIDEMIA

13.5.1

INCREASING ADOPTION OF LONG-ACTING RNA-BASED THERAPIES DRIVES MARKET GROWTH

13.6

OTHER INDICATIONS

NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION

Comprehensive coverage of 7 Regions with country-level deep-dive of 14 Countries | 131 Data Tables.

175

14.1

INTRODUCTION

14.2

NORTH AMERICA

14.2.1

14.2.1.1

FDA APPROVALS, EXPANDING CLINICAL PIPELINES, AND STRATEGIC COLLABORATIONS DRIVE MARKET

14.2.2

CANADA

14.2.2.1

INCREASING ACCESS TO INNOVATIVE NDC THERAPIES DRIVES GROWTH

14.3

EUROPE

14.3.1

GERMANY

14.3.1.1

ACCESS TO INNOVATIVE THERAPIES AND STRONG RADIOLIGAND INFRASTRUCTURE ARE DRIVING GROWTH

14.3.2

14.3.2.1

RISING DEMAND FOR PRECISION ONCOLOGY AND ADVANCED CONJUGATE TECHNOLOGIES DRIVES MARKET EXPANSION

14.3.3

FRANCE

14.3.3.1

BIOPHARMA PRESENCE AND GLOBAL INNOVATION IN TARGETED CONJUGATES SUPPORT MARKET GROWTH

14.3.4

ITALY

14.3.4.1

EXPANDING CLINICAL RESEARCH TO ACCELERATE MARKET GROWTH

14.3.5

SPAIN

14.3.5.1

INCREASED FOCUS ON RESEARCH FOR NDC DEVELOPMENT TO PROPEL MARKET GROWTH

14.3.6

REST OF EUROPE

14.4

ASIA PACIFIC

14.4.1

CHINA

14.4.1.1

STRONG DOMESTIC INNOVATION AND EXPANDING ONCOLOGY DEMAND DRIVE NDC MARKET GROWTH

14.4.2

JAPAN

14.4.2.1

GROWING DRUG APPROVALS AND PHARMA BIOTECH RESEARCH INITIATIVES SUPPORT MARKET GROWTH

14.4.3

INDIA

14.4.3.1

EXPANDING BIOLOGICS CAPABILITIES AND RISING DEMAND FOR TARGETED ONCOLOGY THERAPIES SUPPORT GROWTH

14.4.4

SOUTH KOREA

14.4.4.1

KEY DRUG APPROVALS RELEVANT TO NDC MARKET TO AID GROWTH IN SOUTH KOREA

14.4.5

AUSTRALIA

14.4.5.1

STRONG REGULATORY FRAMEWORK, CLINICAL INNOVATION, AND GLOBAL PARTNERSHIPS DRIVE MARKET GROWTH

14.4.6

REST OF ASIA PACIFIC

14.5

LATIN AMERICA

14.5.1

BRAZIL

14.5.1.1

EXPANDING CLINICAL TRIALS AND RISING DEMAND FOR TARGETED ONCOLOGY THERAPIES DRIVE MARKET GROWTH

14.5.2

MEXICO

14.5.2.1

GRADUAL INCREASE IN PHARMACEUTICAL R&D TO SUPPORT MARKET GROWTH

14.5.3

REST OF LATIN AMERICA

14.6

MIDDLE EAST

14.6.1

GCC COUNTRIES

14.6.1.1

INTEGRATION OF GENOMICS, BIOMARKER-DRIVEN DIAGNOSTICS, AND PERSONALIZED TREATMENT TO PROPEL MARKET

14.6.2

REST OF MIDDLE EAST

14.7

AFRICA

14.7.1

RESEARCH COLLABORATIONS AND INFRASTRUCTURAL DEVELOPMENT TO DRIVE MARKET

COMPETITIVE LANDSCAPE

Discover strategic moves shaping market leaders and emerging disruptors in next-gen drug conjugates.

243

15.1

OVERVIEW

15.2

KEY PLAYER STRATEGIES/RIGHT TO WIN

15.3

REVENUE ANALYSIS, 2021–2025

15.4

MARKET SHARE ANALYSIS

15.5

COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025

15.5.1

STARS

15.5.2

EMERGING LEADERS

15.5.3

PERVASIVE PLAYERS

15.5.4

PARTICIPANTS

15.5.5

COMPANY FOOTPRINT: KEY PLAYERS, 2025

15.5.5.1

COMPANY FOOTPRINT

15.5.5.2

REGION FOOTPRINT

15.5.5.3

TYPE FOOTPRINT

15.5.5.4

INDICATION FOOTPRINT

15.6

COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025

15.6.1

PROGRESSIVE COMPANIES

15.6.2

RESPONSIVE COMPANIES

15.6.3

DYNAMIC COMPANIES

15.6.4

STARTING BLOCKS

15.6.5

COMPETITIVE BENCHMARKING OF STARTUPS/SMES

15.6.5.1

DETAILED LIST OF KEY STARTUPS/SMES

15.7

COMPANY VALUATION AND FINANCIAL METRICS

15.8

BRAND COMPARISON

15.9

COMPETITIVE SCENARIO

15.9.1

PRODUCT APPROVALS

15.9.2

DEALS

15.9.3

EXPANSIONS

COMPANY PROFILES

In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)

264

16.1

KEY PLAYERS

16.1.1

ASTRAZENECA

16.1.1.1

BUSINESS OVERVIEW

16.1.1.2

PRODUCTS OFFERED

16.1.1.3

RECENT DEVELOPMENTS

16.1.1.3.1

PRODUCT APPROVALS

16.1.1.3.2

DEALS

16.1.1.3.3

EXPANSIONS

16.1.1.4

MNM VIEW

16.1.1.4.1

KEY STRENGTHS/RIGHT TO WIN

16.1.1.4.2

STRATEGIC CHOICES MADE

16.1.1.4.3

WEAKNESSES AND COMPETITIVE THREATS

16.1.2

DAIICHI SANKYO COMPANY, LIMITED

16.1.3

NOVARTIS AG

16.1.4

ALNYLAM PHARMACEUTICALS, INC

16.1.5

GILEAD SCIENCES, INC.

16.1.6

IONIS PHARMACEUTICALS, INC.

16.1.7

RAKUTEN GROUP, INC.

16.1.8

NOVO NORDISK

16.1.9

ADC THERAPEUTICS SA

16.1.10

SANOFI

16.1.11

ARROWHEAD PHARMACEUTICALS

16.1.12

ABBVIE INC.

16.1.13

REGENERON PHARMACEUTICALS INC.

16.2

OTHER PLAYERS

16.2.1

BICYCLE THERAPEUTICS

16.2.2

AVIDITY BIOSCIENCES

16.2.3

SILENCE THERAPEUTICS

16.2.4

MEDILINK THERAPEUTICS

16.2.5

SYSTIMMUNE, INC.

16.2.6

ACTINIUM PHARMACEUTICALS

16.2.7

ALPHAMAB ONCOLOGY

16.2.8

FUSION PHARMA

16.2.9

ORANO GROUP

16.2.10

PEPGEN INC

16.2.11

TUBULIS GMBH

16.2.12

CLARITY PHARMACEUTICALS

RESEARCH METHODOLOGY

311

17.1

RESEARCH DATA

17.1.1

SECONDARY DATA

17.1.2

PRIMARY DATA

17.2

MARKET ESTIMATION METHODOLOGY

17.2.1

MARKET SIZE ESTIMATION

17.2.2

INSIGHTS OF PRIMARY EXPERTS

17.2.3

TOP-DOWN APPROACH

17.3

MARKET GROWTH RATE PROJECTIONS

17.4

MARKET BREAKDOWN AND DATA TRIANGULATION

17.5

RESEARCH ASSUMPTIONS

17.6

RESEARCH LIMITATIONS

17.7

RISK ANALYSIS

APPENDIX

322

18.1

DISCUSSION GUIDE

18.2

KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL

18.3

CUSTOMIZATION OPTIONS

18.4

RELATED REPORTS

18.5

AUTHOR DETAILS

LIST OF TABLES

TABLE 1

NEXT-GENERATION DRUG CONJUGATES MARKET: IMPACT ANALYSIS

TABLE 2

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE, 2023–2030 (USD BILLION)

TABLE 3

PHARMACEUTICAL MANUFACTURING SERVICES MARKET FOR SMALL MOLECULES, BY TYPE, 2023–2030 (USD BILLION)

TABLE 4

PHARMACEUTICAL CONTRACT MANUFACTURING MARKET FOR LARGE MOLECULES, BY TYPE, 2023–2030 (USD BILLION)

TABLE 5

BIOCONJUGATION SERVICES MARKET, BY CONJUGATION TYPE, 2022–2029 (USD MILLION)

TABLE 6

NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER’S FIVE FORCES ANALYSIS

TABLE 7

NEXT-GENERATION DRUG CONJUGATES MARKET: ROLE IN ECOSYSTEM

TABLE 8

INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)

TABLE 9

AVERAGE SELLING PRICE TREND, BY REGION, 2023-2025 (USD)

TABLE 10

AVERAGE SELLING PRICE RANGE, BY REGION, 2025 (USD)

TABLE 11

NEXT-GENERATION DRUG CONJUGATES MARKET: KEY CONFERENCES & EVENTS, 2026–2027

TABLE 12

US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 13

CASE STUDIES OF AI IMPLEMENTATION IN NEXT-GENERATION DRUG CONJUGATES MARKET

TABLE 14

CLIENT’S READINESS TO ADOPT GENERATIVE AI

TABLE 15

KEY PIPELINE PRODUCTS IN NEXT-GENERATION DRUG CONJUGATES MARKET (AS OF MARCH 2026)

TABLE 16

EXAMPLES OF US REGULATORY PATHWAY, BY TYPE OF DRUG CONJUGATE

TABLE 17

NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 18

EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 19

ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 20

REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 21

REIMBURSEMENT STATUS AND TYPE, BY COUNTRY

TABLE 22

COUNTRY-WISE REGULATORY SCENARIO FOR NEXT-GENERATION DRUG CONJUGATE MANUFACTURERS

TABLE 23

INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)

TABLE 24

KEY BUYING CRITERIA, BY END USER

TABLE 25

NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 26

NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION)

TABLE 27

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 28

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 29

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 30

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 31

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2024–2035 (USD MILLION)

TABLE 32

NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION)

TABLE 33

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 34

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 35

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 36

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO , BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 37

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PLUVICTO, BY REGION, 2024–2035 (USD MILLION)

TABLE 38

NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION)

TABLE 39

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 40

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 41

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 42

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 43

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMVUTTRA, BY REGION, 2024–2035 (USD MILLION)

TABLE 44

NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION)

TABLE 45

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 46

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 47

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 48

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 49

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR TRODELVY, BY REGION, 2024–2035 (USD MILLION)

TABLE 50

NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION)

TABLE 51

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 52

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 53

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 54

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 55

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SACITUZUMAB TIRUMOTECAN, BY REGION, 2024–2035 (USD MILLION)

TABLE 56

NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION)

TABLE 57

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 58

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 59

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 60

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 61

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PATRITUMAB DERUXTECAN, BY REGION, 2024–2035 (USD MILLION)

TABLE 62

NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION)

TABLE 63

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 64

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 65

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 66

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 67

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR 225AC-PSMA-617, BY REGION, 2024–2035 (USD MILLION)

TABLE 68

NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION)

TABLE 69

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 70

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 71

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 72

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 73

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER COMMERCIALIZED PRODUCTS, BY REGION, 2024–2035 (USD MILLION)

TABLE 74

NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION)

TABLE 75

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 76

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 77

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 78

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 79

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER PIPELINE PRODUCTS, BY REGION, 2024–2035 (USD MILLION)

TABLE 80

NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 81

ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 82

NORTH AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 83

EUROPE: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 84

ASIA PACIFIC: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 85

LATIN AMERICA: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 86

MIDDLE EAST: ANTIBODY–SMALL MOLECULE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 87

PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 88

NORTH AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 89

EUROPE: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 90

ASIA PACIFIC: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 91

LATIN AMERICA: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 92

MIDDLE EAST: PEPTIDE–RADIONUCLIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 93

LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 94

NORTH AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 95

EUROPE: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 96

ASIA PACIFIC: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 97

LATIN AMERICA: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 98

MIDDLE EAST: LIGAND–OLIGONUCLEOTIDE CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 99

OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 100

NORTH AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 101

EUROPE: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 102

ASIA PACIFIC: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 103

LATIN AMERICA: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 104

MIDDLE EAST: OTHER NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 105

NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 106

NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION)

TABLE 107

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 108

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 109

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 110

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 111

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR ANTIBODIES, BY REGION, 2024–2035 (USD MILLION)

TABLE 112

NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION)

TABLE 113

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 114

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 115

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 116

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 117

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR AMINO SUGARS, BY REGION, 2024–2035 (USD MILLION)

TABLE 118

NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION)

TABLE 119

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 120

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 121

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 122

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 123

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL MOLECULES, BY REGION, 2024–2035 (USD MILLION)

TABLE 124

NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION)

TABLE 125

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 126

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 127

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 128

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 129

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PEPTIDES, BY REGION, 2024–2035 (USD MILLION)

TABLE 130

NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 131

NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)

TABLE 132

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 133

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 134

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 135

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 136

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR SMALL-MOLECULE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)

TABLE 137

NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)

TABLE 138

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 139

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 140

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 141

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 142

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OLIGONUCLEOTIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)

TABLE 143

NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)

TABLE 144

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 145

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 146

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 147

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 148

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR RADIONUCLIDE PAYLOADS, BY REGION, 2024–2035 (USD MILLION)

TABLE 149

NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 150

NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION)

TABLE 151

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 152

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 153

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 154

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 155

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2024–2035 (USD MILLION)

TABLE 156

NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION)

TABLE 157

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 158

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 159

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 160

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 161

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR HATTR WITH POLYNEUROPATHY, BY REGION, 2024–2035 (USD MILLION)

TABLE 162

NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION)

TABLE 163

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 164

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 165

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 166

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 167

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PROSTATE CANCER, BY REGION, 2024–2035 (USD MILLION)

TABLE 168

NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION)

TABLE 169

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 170

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 171

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 172

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 173

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR PRIMARY HYPERLIPIDEMIA, BY REGION, 2024–2035 (USD MILLION)

TABLE 174

NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION)

TABLE 175

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 176

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 177

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 178

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 179

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2035 (USD MILLION)

TABLE 180

NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 181

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 182

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 183

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 184

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 185

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 186

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 187

US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 188

US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 189

US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 190

US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 191

US: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 192

CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 193

CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 194

CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 195

CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 196

CANADA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 197

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 198

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 199

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 200

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 201

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 202

EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 203

GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 204

GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 205

GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 206

GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 207

GERMANY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 208

UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 209

UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 210

UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 211

UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 212

UK: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 213

FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 214

FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 215

FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 216

FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 217

FRANCE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 218

ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 219

ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 220

ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 221

ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 222

ITALY: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 223

SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 224

SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 225

SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 226

SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 227

SPAIN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 228

REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 229

REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 230

REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 231

REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 232

REST OF EUROPE: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 233

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 234

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 235

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 236

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 237

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 238

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 239

CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 240

CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 241

CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 242

CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 243

CHINA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 244

JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 245

JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 246

JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 247

JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 248

JAPAN: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 249

INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 250

INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 251

INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 252

INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 253

INDIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 254

SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 255

SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 256

SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 257

SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 258

SOUTH KOREA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 259

AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 260

AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 261

AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 262

AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 263

AUSTRALIA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 264

REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 265

REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 266

REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 267

REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 268

REST OF ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 269

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY COUNTRY, 2024–2035 (USD MILLION)

TABLE 270

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 271

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 272

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 273

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 274

LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 275

BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 276

BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 277

BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 278

BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 279

BRAZIL: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 280

MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 281

MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 282

MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 283

MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 284

MEXICO: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 285

REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 286

REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 287

REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 288

REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 289

REST OF LATIN AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 290

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY REGION, 2024–2035 (USD MILLION)

TABLE 291

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 292

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 293

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 294

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 295

MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 296

GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 297

GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 298

GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 299

GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 300

GCC COUNTRIES: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 301

REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 302

REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 303

REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 304

REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 305

REST OF MIDDLE EAST: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 306

AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PRODUCT, 2024–2035 (USD MILLION)

TABLE 307

AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TYPE, 2024–2035 (USD MILLION)

TABLE 308

AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY TARGET LIGAND, 2024–2035 (USD MILLION)

TABLE 309

AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2024–2035 (USD MILLION)

TABLE 310

AFRICA: NEXT-GENERATION DRUG CONJUGATES MARKET, BY INDICATION, 2024–2035 (USD MILLION)

TABLE 311

STRATEGIES ADOPTED BY KEY PLAYERS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2023−2026

TABLE 312

NEXT-GENERATION DRUG CONJUGATES MARKET: DEGREE OF COMPETITION

TABLE 313

NEXT-GENERATION DRUG CONJUGATES MARKET: REGION FOOTPRINT

TABLE 314

NEXT-GENERATION DRUG CONJUGATES MARKET: TYPE FOOTPRINT

TABLE 315

NEXT-GENERATION DRUG CONJUGATES MARKET: INDICATION FOOTPRINT

TABLE 316

NEXT-GENERATION DRUG CONJUGATES MARKET: KEY STARTUPS/SMES

TABLE 317

NEXT-GENERATION DRUG CONJUGATES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES

TABLE 318

NEXT-GENERATION DRUG CONJUGATES MARKET: PRODUCT APPROVALS, JANUARY 2023 TO MARCH 2026

TABLE 319

NEXT-GENERATION DRUG CONJUGATES MARKET: DEALS, JANUARY 2023 TO MARCH 2026

TABLE 320

NEXT-GENERATION DRUG CONJUGATES MARKET: EXPANSIONS, JANUARY 2023 TO MARCH 2026

TABLE 321

ASTRAZENECA: COMPANY OVERVIEW

TABLE 322

ASTRAZENECA: PRODUCTS OFFERED

TABLE 323

ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2023– MARCH 2026

TABLE 324

ASTRAZENECA: DEALS, JANUARY 2023–MARCH 2026

TABLE 325

ASTRAZENECA: EXPANSIONS, JANUARY 2023–MARCH 2026

TABLE 326

DAIICHI SANKYO COMPANY, LIMITED: COMPANY OVERVIEW

TABLE 327

DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS OFFERED

TABLE 328

DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS IN PIPELINE

TABLE 329

DAIICHI SANKYO COMPANY, LIMITED: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026

TABLE 330

DAIICHI SANKYO COMPANY, LIMITED: EXPANSIONS, JANUARY 2023–MARCH 2026

TABLE 331

NOVARTIS AG: COMPANY OVERVIEW

TABLE 332

NOVARTIS AG: PRODUCTS OFFERED

TABLE 333

NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026

TABLE 334

NOVARTIS AG: DEALS, JANUARY 2023–MARCH 2026

TABLE 335

NOVARTIS AG: EXPANSIONS, JANUARY 2023–MARCH 2026

TABLE 336

ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW

TABLE 337

ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED

TABLE 338

ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026

TABLE 339

ALNYLAM PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–MARCH 2026

TABLE 340

ALNYLAM PHARMACEUTICALS INC.: EXPANSIONS, JANUARY 2023–MARCH 2026

TABLE 341

GILEAD SCIENCES, INC.: COMPANY OVERVIEW

TABLE 342

GILEAD SCIENCES, INC.: PRODUCTS OFFERED

TABLE 343

GILEAD SCIENCES, INC.: DEALS, JANUARY 2023–MARCH 2026

TABLE 344

GILEAD SCIENCES, INC.: EXPANSIONS, JANUARY 2023–MARCH 2026

TABLE 345

IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW

TABLE 346

IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED

TABLE 347

IONIS PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE

TABLE 348

IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026

TABLE 349

IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2023–MARCH 2026

TABLE 350

RAKUTEN GROUP, INC.: COMPANY OVERVIEW

TABLE 351

RAKUTEN GROUP, INC.: PRODUCTS IN PIPELINE

TABLE 352

RAKUTEN GROUP, INC.: DEALS, JANUARY 2023–MARCH 2026

TABLE 353

NOVO NORDISK: COMPANY OVERVIEW

TABLE 354

NOVO NORDISK: PRODUCTS OFFERED

TABLE 355

NOVO NORDISK: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026

TABLE 356

NOVO NORDISK: DEALS, JANUARY 2023–MARCH 2026

TABLE 357

ADC THERAPEUTICS SA: COMPANY OVERVIEW

TABLE 358

ADC THERAPEUTICS SA: PRODUCTS OFFERED

TABLE 359

ADC THERAPEUTICS SA: PRODUCTS IN PIPELINE

TABLE 360

SANOFI: COMPANY OVERVIEW

TABLE 361

SANOFI: PRODUCTS OFFERED

TABLE 362

SANOFI: PRODUCTS IN PIPELINE

TABLE 363

SANOFI: DEALS, JANUARY 2023–MARCH 2026

TABLE 364

ARROWHEAD PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 365

ARROWHEAD PHARMACEUTICALS: PIPELINE PRODUCTS

TABLE 366

ARROWHEAD PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2023–MARCH 2026

TABLE 367

ABBVIE INC.: COMPANY OVERVIEW

TABLE 368

ABBVIE INC.: PRODUCTS IN PIPELINE

TABLE 369

REGENERON PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 370

REGENERON PHARMACEUTICALS INC.: PRODUCTS IN PIPELINE

TABLE 371

BICYCLE THERAPEUTICS: COMPANY OVERVIEW

TABLE 372

AVIDITY BIOSCIENCES: COMPANY OVERVIEW

TABLE 373

SILENCE THERAPEUTICS: COMPANY OVERVIEW

TABLE 374

MEDILINK THERAPEUTICS: COMPANY OVERVIEW

TABLE 375

SYSTIMMUNE, INC.: COMPANY OVERVIEW

TABLE 376

ACTINIUM PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 377

ALPHAMAB ONCOLOGY: COMPANY OVERVIEW

TABLE 378

FUSION PHARMA: COMPANY OVERVIEW

TABLE 379

ORANO GROUP: COMPANY OVERVIEW

TABLE 380

PEPGEN INC.: COMPANY OVERVIEW

TABLE 381

TUBULIS GMBH: COMPANY OVERVIEW

TABLE 382

CLARITY PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 383

IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS

LIST OF FIGURES

FIGURE 1

MARKET SCENARIO

FIGURE 2

GLOBAL NEXT-GENERATION DRUG CONJUGATES MARKET, 2024–2035

FIGURE 3

MAJOR STRATEGIES ADOPTED BY KEY MARKET PLAYERS, 2023–2026

FIGURE 4

DISRUPTIONS INFLUENCING GROWTH OF NEXT-GENERATION DRUG CONJUGATES MARKET

FIGURE 5

HIGH-GROWTH SEGMENTS IN NEXT-GENERATION DRUG CONJUGATES MARKET, 2026–2035

FIGURE 6

NORTH AMERICA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

FIGURE 7

TECHNOLOGICAL ADVANCEMENTS IN LINKER CHEMISTRY AND PAYLOAD DEVELOPMENT TO DRIVE GROWTH

FIGURE 8

ANTIBODY SEGMENT IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2025

FIGURE 9

CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

FIGURE 10

NEXT-GENERATION DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 11

NEXT-GENERATION DRUG CONJUGATES MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 12

NEXT-GENERATION DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS

FIGURE 13

NEXT-GENERATION DRUG CONJUGATES MARKET: ECOSYSTEM ANALYSIS

FIGURE 14

INDICATIVE SELLING PRICE OF PRODUCTS, BY KEY PLAYER, 2025 (USD)

FIGURE 15

INDICATIVE SELLING PRICE, BY REGION, 2025 (USD)

FIGURE 16

NEXT-GENERATION DRUG CONJUGATES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

FIGURE 17

VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE

FIGURE 18

IMPACT OF AI/GEN AI ON NEXT-GENERATION DRUG CONJUGATES MARKET

FIGURE 19

INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE

FIGURE 20

KEY BUYING CRITERIA, BY END USER

FIGURE 21

NORTH AMERICA: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT

FIGURE 22

ASIA PACIFIC: NEXT-GENERATION DRUG CONJUGATES MARKET SNAPSHOT

FIGURE 23

REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)

FIGURE 24

MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)

FIGURE 25

NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025

FIGURE 26

NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY FOOTPRINT

FIGURE 27

NEXT-GENERATION DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025

FIGURE 28

EV/EBITDA OF KEY VENDORS

FIGURE 29

YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 30

NEXT-GENERATION DRUG CONJUGATES MARKET: BRAND COMPARATIVE ANALYSIS

FIGURE 31

ASTRAZENECA: COMPANY SNAPSHOT (2025)

FIGURE 32

DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2024)

FIGURE 33

NOVARTIS AG: COMPANY SNAPSHOT (2025)

FIGURE 34

ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)

FIGURE 35

GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025)

FIGURE 36

IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2024)

FIGURE 37

RAKUTEN GROUP, INC.: COMPANY SNAPSHOT (2025)

FIGURE 38

NOVO NORDISK: COMPANY SNAPSHOT (2025)

FIGURE 39

ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2025)

FIGURE 40

SANOFI: COMPANY SNAPSHOT (2025)

FIGURE 41

ARROWHEAD PHARMACEUTICALS: COMPANY SNAPSHOT (2025)

FIGURE 42

RESEARCH DESIGN

FIGURE 43

NEXT-GENERATION DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES

FIGURE 44

NEXT-GENERATION DRUG CONJUGATES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025

FIGURE 45

MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025

FIGURE 46

REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF ALNYLAM PHARMACEUTICALS (2025)

FIGURE 47

MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 48

MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

FIGURE 49

NEXT-GENERATION DRUG CONJUGATES MARKET CAGR PROJECTIONS

FIGURE 50

DATA TRIANGULATION METHODOLOGY

Methodology

This study involved four major activities in estimating the current size of the next generation drug conjugates market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), CT.gov, EudraCT, other clinical trial registries, News Articles, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global next generation drug conjugates market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Next Generation Drug Conjugates NDCS Markett
Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the next generation drug conjugates market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Next Generation Drug Conjugates NDCS Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; the data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Drug conjugates are targeted therapeutic systems in which a biologically or chemically engineered targeting moiety (e.g., antibody, peptide, small-molecule ligand, or oligonucleotide delivery ligand) is conjugated to a therapeutic payload (e.g., cytotoxic drug, radionuclide, or nucleic acid) using linker or conjugation technologies. Next generation drug conjugates are defined by the use of advanced targeting platforms and/or novel payload technologies—particularly small molecules (e.g., topoisomerases, others), radionuclides, and oligonucleotides, enabled by improved linker and conjugation strategies, distinguishing them from earlier auristatin, maytansinoid, and calicheamicin-based conjugates. These enable improved precision, efficacy, and safety compared to earlier-generation conjugates.

Key Stakeholders

Next generation drug conjugate manufacturing companies
Distributors and suppliers of next generation drug conjugates
Healthcare service providers (including hospitals & specialty clinics)
National and regional research boards and organizations
Research & development companies
Clinical research organizations (CROs)
Biotechnology companies
Research laboratories & academic institutes
Market research & consulting firms
Regulatory bodies

Report Objectives

To define, describe, and forecast the next generation drug conjugates market by product type, target ligand, payload type, indication, and region
To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall next generation drug conjugates market
To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
To profile the key players and analyze their market shares and core competencies
To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis

Further breakdown of the Rest of Europe next generation drug conjugates market, by country
Further breakdown of the Rest of Asia Pacific next generation drug conjugates market, by country

Company Information

Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

Cross-segment analysis

REPORT COVERAGE

＋

REPORT OVERVIEW
KEY TAKEAWAYS
TRENDS/DISRUPTIONS IMPACT
MARKET DYNAMICS
MARKET ECOSYSTEM
MARKET SEGMENTS
MARKET REGION
COMPANY EVALUATION MATRIX
KEY MARKET PLAYERS
REPORT SCOPE
WHAT'S IN IT FOR YOU
DELIVERED CUSTOMIZATION
RECENT DEVELOPMENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report

Fact checked

Cite this Research

Personalize This Research

Triangulate with your Own Data
Get Data as per your Format and Definition
Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
Any level of Personalization

Request A Free Customisation

Let Us Help You

What are the Known and Unknown Adjacencies Impacting the Next Generation Drug Conjugates Market
What will your New Revenue Sources be?
Who will be your Top Customer; what will make them switch?
Defend your Market Share or Win Competitors
Get a Scorecard for Target Partners

Customized Workshop Request

TESTIMONIALS

JAYANT RAJPUROHIT

Director of Market Insights, Data and Analytics

SFI Health,

Leading Pharmaceutical Company

www.sfihealth.com/

We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.

BEATRIZ DE LA CALLE

Head of Commercial Analytics

Qualicaps,

Leading Pharmaceutical Company

www.qualicaps.com/

We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.

Bob Williams,

Senior Director Business Development & Innovation

Bracco Diagnostics Inc.,

Italian Multinational in life sciences sector and a World Leader in imaging diagnostics

imaging.bracco.com/us-en

We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.

Cody Coonradt,

Market Development and Strategy Manager

3M Health Information Systems,

Leader in Health care Coding, Payment & Analytics Solutions.

www.3m.com/3M/en_US/health-information-systems-us

The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.

Their customer first approach and high value engagement model, have given us great analysis and excellent value for money